Amicus Therapeutics announces United Kingdom’s MHRA grants early access to AT-GAA

Amicus Therapeutics

8 June 2021 - Permits All Eligible Individuals with Late-Onset Pompe Disease Access to AT-GAA Prior to Marketing Authorization in the UK.

Amicus Therapeutics today announced that the UK’s MHRA has granted a positive scientific opinion through the Early Access to Medicines Scheme to AT-GAA, the Company’s investigational two-component therapy for the treatment of Pompe disease.

Read Amicus Therapeutics press release 

Michael Wonder

Posted by:

Michael Wonder

Posted in:

England , Medicine , Market access